Dermatitis News

In this edition, allergic illnesses in children may be inherited from mothers; addressing needs of Muslim patients in dermatology; YouTube content on topical steroid withdrawal exhibits poor reliability and more.

The FDA has accepted the supplemental new drug application for roflumilast cream 0.15% for adults and children aged as young as 6 years with atopic dermatitis, Arcutis Biotherapeutics announced in a press release.

Children born to mothers with atopic dermatitis are more prone to develop atopic dermatitis as well as other allergic illnesses, according to a study.

Long-term trial results showed efficacy of rademikibart in Chinese patients with moderate to severe atopic dermatitis, Connect Biopharma announced in a press release.

The European Commission has approved Ebglyss in the European Union for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, Almirall announced in a press release.

Results from a phase 1 study show that KT-474 reduced disease-relevant inflammatory biomarkers in the blood and skin of patients with hidradenitis suppurativa or atopic dermatitis, according to a Kymera Therapeutics press release.

ANAHEIM, Calif. — Tapinarof cream was well tolerated and significantly improved itch in adults and children aged as young as 2 years with atopic dermatitis, according to a poster presentation here.

In patients with atopic dermatitis treated with dupilumab, a reversible and most likely benign lymphoid reaction could occur, according to a study.

ANAHEIM, Calif. — Patients with atopic dermatitis achieved long-term disease control with as-needed use of ruxolitinib cream, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Patients with atopic dermatitis with comorbidities face additional treatment burdens and barriers, according to a study published in Annals of Allergy, Asthma & Immunology.